Literature DB >> 11811784

Distribution of the human immunodeficiency virus coreceptors CXCR4 and CCR5 on leukocytes of persons with human immunodeficiency virus type 1 infection and pulmonary tuberculosis: implications for pathogenesis.

S Shalekoff1, S Pendle, D Johnson, D J Martin, C T Tiemessen.   

Abstract

Expression of CXCR4 was significantly reduced from normal on all cell subsets of persons with pulmonary tuberculosis (TB group), with HIV-1 infection (HIV group), and those with both infections (HIV/TB group), except for on monocytes in the HIV group. The reductions were most notable in the two TB groups. Interestingly, the duration of antituberculosis treatment was significantly negatively correlated with the expression of CXCR4 on CD4+ and CD8+CD45RO+ cells, monocytes and NK cells, viral load, and proportions of CD38-expressing CD8+ lymphocytes, in HIV/TB patients. By contrast, CCR5 expression on most cell subsets analyzed was increased in all the disease groups, except for on monocytes in the two TB groups. There was no change in CCR5 expression on CD4+ cells when based on the disease groupings. However, higher proportions of CD4+CD45RA+ and CD8+ lymphocytes as well as B cells expressing CCR5 correlated with advancing HIV-1 disease, as did decreased proportions of CXCR4-expressing CD4+CD45RA+ cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11811784     DOI: 10.1023/a:1013121625962

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  35 in total

1.  HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5.

Authors:  T Dragic; V Litwin; G P Allaway; S R Martin; Y Huang; K A Nagashima; C Cayanan; P J Maddon; R A Koup; J P Moore; W A Paxton
Journal:  Nature       Date:  1996-06-20       Impact factor: 49.962

2.  The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates.

Authors:  H Choe; M Farzan; Y Sun; N Sullivan; B Rollins; P D Ponath; L Wu; C R Mackay; G LaRosa; W Newman; N Gerard; C Gerard; J Sodroski
Journal:  Cell       Date:  1996-06-28       Impact factor: 41.582

3.  A new classification for HIV-1.

Authors:  E A Berger; R W Doms; E M Fenyö; B T Korber; D R Littman; J P Moore; Q J Sattentau; H Schuitemaker; J Sodroski; R A Weiss
Journal:  Nature       Date:  1998-01-15       Impact factor: 49.962

4.  Depressed phagocytosis and oxidative burst in polymorphonuclear leukocytes from individuals with pulmonary tuberculosis with or without human immunodeficiency virus type 1 infection.

Authors:  S Shalekoff; C T Tiemessen; C M Gray; D J Martin
Journal:  Clin Diagn Lab Immunol       Date:  1998-01

5.  Patients with active tuberculosis have increased expression of HIV coreceptors CXCR4 and CCR5 on CD4(+) T cells.

Authors:  N P Juffermans; P Speelman; A Verbon; J Veenstra; C Jie; S J van Deventer; T van Der Poll
Journal:  Clin Infect Dis       Date:  2001-02-07       Impact factor: 9.079

6.  Reduced expression of interleukin-8 receptors A and B on polymorphonuclear neutrophils from persons with human immunodeficiency virus type 1 disease and pulmonary tuberculosis.

Authors:  S Meddows-Taylor; D J Martin; C T Tiemessen
Journal:  J Infect Dis       Date:  1998-04       Impact factor: 5.226

7.  Influence of tuberculosis on human immunodeficiency virus (HIV-1): enhanced cytokine expression and elevated beta 2-microglobulin in HIV-1-associated tuberculosis.

Authors:  R S Wallis; M Vjecha; M Amir-Tahmasseb; A Okwera; F Byekwaso; S Nyole; S Kabengera; R D Mugerwa; J J Ellner
Journal:  J Infect Dis       Date:  1993-01       Impact factor: 5.226

8.  Chemokine coreceptor usage by diverse primary isolates of human immunodeficiency virus type 1.

Authors:  L Zhang; T He; Y Huang; Z Chen; Y Guo; S Wu; K J Kunstman; R C Brown; J P Phair; A U Neumann; D D Ho; S M Wolinsky
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

9.  Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study.

Authors:  M Dean; M Carrington; C Winkler; G A Huttley; M W Smith; R Allikmets; J J Goedert; S P Buchbinder; E Vittinghoff; E Gomperts; S Donfield; D Vlahov; R Kaslow; A Saah; C Rinaldo; R Detels; S J O'Brien
Journal:  Science       Date:  1996-09-27       Impact factor: 47.728

10.  Interleukin 10 increases CCR5 expression and HIV infection in human monocytes.

Authors:  S Sozzani; S Ghezzi; G Iannolo; W Luini; A Borsatti; N Polentarutti; A Sica; M Locati; C Mackay; T N Wells; P Biswas; E Vicenzi; G Poli; A Mantovani
Journal:  J Exp Med       Date:  1998-02-02       Impact factor: 14.307

View more
  12 in total

1.  Marked differences in CCR5 expression and activation levels in two South African populations.

Authors:  Anabela C P Picton; Sharon Shalekoff; Maria Paximadis; Caroline T Tiemessen
Journal:  Immunology       Date:  2012-08       Impact factor: 7.397

2.  Clinical investigation: increased serum stromal derived factor 1 alpha levels in pulmonary tuberculosis.

Authors:  K Mizuno; W Matsuyama; H Mitsuyama; M Watanabe; I Higashimoto; M Osame; K Arimura
Journal:  Clin Exp Immunol       Date:  2005-03       Impact factor: 4.330

3.  CCR5 promoter haplotypes differentially influence CCR5 expression on natural killer and T cell subsets in ethnically divergent HIV-1 uninfected South African populations.

Authors:  Anabela C P Picton; Maria Paximadis; Caroline T Tiemessen
Journal:  Immunogenetics       Date:  2012-08-15       Impact factor: 2.846

4.  In vivo CXCR4 expression, lymphoid cell phenotype, and feline immunodeficiency virus infection.

Authors:  Sean P Troth; Alan D Dean; Edward A Hoover
Journal:  Vet Immunol Immunopathol       Date:  2008-01-19       Impact factor: 2.046

5.  Natural killer cells in HIV-1 infection: dichotomous effects of viremia on inhibitory and activating receptors and their functional correlates.

Authors:  Domenico Mavilio; Janet Benjamin; Marybeth Daucher; Gabriella Lombardo; Shyam Kottilil; Marie A Planta; Emanuela Marcenaro; Cristina Bottino; Lorenzo Moretta; Alessandro Moretta; Anthony S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-25       Impact factor: 11.205

6.  Impairment of beta chemokine and cytokine production in patients with HIV related Pneumocystis jerovici pneumonia.

Authors:  D Israël-Biet; H Esvant; A M Laval; J Cadranel
Journal:  Thorax       Date:  2004-03       Impact factor: 9.139

7.  Maraviroc as intensification strategy in HIV-1 positive patients with deficient immunological response: an Italian randomized clinical trial.

Authors:  Stefano Rusconi; Paola Vitiello; Fulvio Adorni; Elisa Colella; Emanuele Focà; Amedeo Capetti; Paola Meraviglia; Clara Abeli; Stefano Bonora; Marco D'Annunzio; Antonio Di Biagio; Massimo Di Pietro; Luca Butini; Giancarlo Orofino; Manuela Colafigli; Gabriella d'Ettorre; Daniela Francisci; Giustino Parruti; Alessandro Soria; Anna Rita Buonomini; Chiara Tommasi; Silvia Mosti; Francesca Bai; Silvia Di Nardo Stuppino; Manuela Morosi; Marco Montano; Pamela Tau; Esther Merlini; Giulia Marchetti
Journal:  PLoS One       Date:  2013-11-14       Impact factor: 3.240

8.  Enhancement of HIV-1 infection and intestinal CD4+ T cell depletion ex vivo by gut microbes altered during chronic HIV-1 infection.

Authors:  Stephanie M Dillon; Eric J Lee; Andrew M Donovan; Kejun Guo; Michael S Harper; Daniel N Frank; Martin D McCarter; Mario L Santiago; Cara C Wilson
Journal:  Retrovirology       Date:  2016-01-14       Impact factor: 4.602

Review 9.  C-C chemokine receptor type five (CCR5): An emerging target for the control of HIV infection.

Authors:  Fatima Barmania; Michael S Pepper
Journal:  Appl Transl Genom       Date:  2013-05-26

10.  Modulation of Cell Surface Receptor Expression by Modified Vaccinia Virus Ankara in Leukocytes of Healthy and HIV-Infected Individuals.

Authors:  Adrien Leite Pereira; Quentin Jouhault; Ernesto Marcos Lopez; Antonio Cosma; Olivier Lambotte; Roger Le Grand; Michael H Lehmann; Nicolas Tchitchek
Journal:  Front Immunol       Date:  2020-09-08       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.